Skip to main content

Table. 2 Evolution of lipid parameters

From: Impact of switch from tenofovir disoproxil fumarate-based regimens to tenofovir alafenamide-based regimens on lipid profile, weight gain and cardiovascular risk score in people living with HIV

A. TDF/TDF group, Mean [95%CI] (N = 31)

 

N

2016

2018

Evolution

2018–2016

p-value

Triglycerides (mg/dL)

31

134 [104;164]

116 [91;141]

− 18 [− 49;13]

0.26

TC (mg/dL)

31

184 [170;199]

176 [161;191]

− 8.5 [− 16;− 1.0]

0.028

LDL Cholesterol (mg/dL)

1

107 [94;119]

103 [89;117]

− 3.8 [− 12;4.8]

0.38

HDL Cholesterol (mg/dL)

31

51 [47;56]

50 [45;55]

− 1.2 [− 4.3;1.9]

0.44

TC/HDL ratio

31

3.8 [3.4;4.3]

3.7 [3.3;4.2]

− 0.087 [− 0.37;0.19]

0.53

B. Evolution of lipid parameters in TDF/TAF group, Mean [95%CI] (N = 98)

 

N

Before

(on TDF)

After

(on TAF)

Evolution

AfterBefore

p-value

Triglycerides (mg/dL)

98

123 [110;136]

143 [124;161]

20 [7;33]

0.0026

TC (mg/dL)

98

183 [176;191]

192 [185;199]

8.7 [3.1; 14]

0.0026

LDL Cholesterol (mg/dL)

95

103 [97;110

105 [99;111]

1.7 [− 3.0;6.4]

0.48

HDL Cholesterol (mg/dL)

96

56 [52;53]

59 [55;63]

2.9 [0.75;5.0]

0.0084

TC/HDL ratio

96

3.6 [3.3;3.8]

3.5 [3.3;3.8]

− 0.023 [− 0.18;0.13]

0.77